Full Press Release Details
Jaguar Health Reports Voting Results from 2021
Annual Meeting of Stockholders
Proposals 1, 2, 4, 5 & 6 approved
San Francisco, CA (September 3, 2021): Jaguar Health, Inc. (NASDAQ:
JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 2021 Annual
Meeting of Stockholders, which was adjourned until September 3, 2021.
Six items of business were addressed at the meeting today:
Proposals 1, 2, 4, 5 and 6 were submitted to and approved today by
Jaguar stockholders at the Annual Meeting. With respect to Proposal 5, the non-binding frequency selected by the stockholders is three
years. Although over 75% of votes cast for Proposal 3 were in favor of the proposal, an insufficient number of votes were received from
stockholders for this proposal to be approved.
The proposals are described in detail in Jaguar's definitive
proxy statement on Schedule 14A relating to the Annual Meeting filed with the SEC on filed April 13, 2021. Stockholders may obtain a free
copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available
on Jaguar's corporate website.
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo
Jaguar Health, Inc. is a commercial stage pharmaceuticals company
focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI
distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on
developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from
rainforest areas. Our Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of
noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine
approved under FDA Botanical Guidance. Napo EU S.p.A., the wholly owned Italian subsidiary of Napo Pharmaceuticals, focuses on
expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for
gross proceeds of approximately 8,830,000 euros.
For more information about Jaguar, please visit https://jaguar.health.
For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
Mytesi (crofelemer delayed release tablets) is an antidiarrheal
indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi .
If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate
therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo
were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements." In some cases, you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "aim," "anticipate," "could," "intend,"
"target," "project," "contemplate," "believe," "estimate," "predict,"
"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements
in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections
about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks,
uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except
as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether
as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.